The aim of this research is to investigate the significance of clusterin (CLU) expression as a risk factor for breast cancer through tissue microarray technology and univariate analysis of overall survival. Formalin-fixed, paraffin-embedded tissues from 158 cases of breast cancer and 31 cases of normal adjacent tissues assembled into a tissue microarray. Cytoplasmic CLU expression in tumor tissues was measured by immunochemistry. Survival analysis was used to investigate the relationship between CLU expression and prognosis, tumor volume, pathological classification, and recurrence. Survival time of patients with CLU expression, lymph node metastasis, and limited post-surgery chemotherapy (<6 cycles of treatment) was significantly shorter than that of patients with no detectable CLU expression (P=0.000), without lymph node metastasis (P=0.000) and more comprehensive post-surgery chemotherapy (≥6 cycles of treatment) (P=0.035). CLU expression in tumor cells was higher than in normal adjacent breast epithelial cells (P=0.03). The CLU expression staining coefficient of cancer tissues with lymph node metastasis was higher than those without lymph node metastasis (P=0.000). Cytoplasmic CLU expression was found to be a prognostic factor for human breast cancer.
Introduction
Systemic treatment is an important mainstay for breast cancer therapy, but some patients with late stage disease who are treated this way still succumb to recurrence and metastasis. Metastasis of breast cancer is the main cause of therapy failure (1, 2) . Currently, the cornerstone of effective breast cancer treatment is early detection and anti-metastasis therapy. The prognosis for patients with breast cancer is associated with the tumor histology grade, tumor volume, and lymph node metastasis. In this study, we investigated the relationship between breast cancer prognosis and the tumor histology grade, tumor volume, and recurrence through long-term follow-up of 158 breast cancer patients.
Clusterin (CLU) is found in all human fluids, and its expression is widely distributed in various tissues (3) (4) (5) . It is involved in many important processes including lipid transport, programmed cell death, membrane recycling, cell adhesion, and epithelial cell differentiation. The isoform and localization of CLU correlate to tumor growth and metastasis (6) (7) (8) . In this study, CLU expression in 158 cases of breast cancer tissues and 31 cases of normal breast epithelial tissues was detected, and the function of CLU in carcinogenesis and metastasis of breast cancer was also investigated. Recently, it has come to light that there are two forms of CLU, a secreted and a nuclear form. Mature secreted clusterin (sCLU) is a 70-80 kDa dimeric glycoprotein. The uncleaved 60kDa form of sCLU is found in the endoplasmic reticulum. This form is cleaved between Arg205 and Ser206 to produce the αand β-subunits, which then associate through disulfide bonds and become glycosylated (9). Nuclear clusterin (nCLU) is not glycosylated, is expressed in latent form in the cytosol. Its overexpression is thought to be a death signal that inhibits normal cell growth. Some studies suggest nCLU may induce cell death by cytotoxic events (10, 11) . nCLU in normal cells also induces cell death (12, 13) . In this study, we investigated the clinical significance of the secreted form of clusterin expression in human breast cancer.
Materials and Methods

Patient Population
From 1993 to 1994, we recruited a cohort of 158 breast cancer patients who had undergone surgery and chemotherapy at Tianjin Cancer Hospital. All the patients have a detailed pathologic and clinical data and treated with tamoxifen after surgery. The chemotherapy consisted of CMF (Cyclop hospamide+Methotrexate+5-Fluorouracil). Data including age, prognosis, tumor volume, recurrence, and histology grade were collected for the 158 patients. Follow-up ended on June 1, 2006, when 52 cases had died and 106 cases survived (survival rate of 67.1%).
Case Information
The median age of patients was 50.52 ± 11.55 years (range 30-80 years); and the median survival time was 92.41 ± 42.36 months (range 6.63-161 months). There were 28 patients younger than 40 years old, and 130 patients were 40 or older. Nearly 75% of the patients were between 35 and 55 years old. Twenty-eight patients were treated with surgery alone, and 130 patients were treated with surgery and chemotherapy. Lymph node metastasis occurred in 94 cases, and recurrence occurred in 55 cases. One hundred fifty-two patients were diagnosed with invasive ductal carcinoma, one patient was diagnosed with invasive lobular carcinoma, and five patients were diagnosed with a special type of invasive ductal carcinoma. The clinical-pathological features for the 158 patients (see Table I ).
Tissue Microarray Construction
Formalin-fixed, paraffin-embedded tissues from 158 breast cancer samples were analyzed after staining with standard hematoxylin and eosin, and then specific tissues were chosen to make a tissue microarray with 1 mm cores (1 mm between cores). The glass slides were purchased from Zhongshan Inc., and the cover slips were washed in 75% alcohol and 1% hydrochloric acid before using. Immunohistochemical staining was performed on the tissue microarray sections.
Immunohistochemistry
Immunohistochemical staining was performed using rabbit polyclonal antibody to clusterin α and β subunits (Clone H-330, Santa Cruz Biotechnology Inc.; diluted 1:100). The antibody can detect CLU expression in the cytoplasm and is not specific for nuclear clusterin. After the tissue microarray sections were cut and placed on slides, they were air-dried and the tissue was deparaffinized. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in 50% methanol for 10 min at room temperature. Then the slides were pretreated with citrate buffer (0.01 M citric acid, pH 6.0) for 20 min at 100 ºC to expose epitopes in the microwave, After nonspecific binding sites were blocked by exposure to 2% normal goat serum in phosphate-buffered saline (PBS) for 20 min at 37 ºC, the sections were incubated overnight at 4 ºC with rabbit polyclonal anti-clusterin and then the sections were incubated with pan-SP9000 (Beijing Zhongshan Inc.) for coloration after hybridization. The microarrays were counterstained with hematoxylin to visualize the cell nuclei, dehydrated in ethanol, and cleared in xylene, and then the cover slips were mounted.
Counting Methods
The judgment of clusterin (CLU) staining results was based on the multiplication of the points scored for the CLU stain- ing intensity (1, slight yellow staining; 2, strong staining) and the points scored for the percentage of cells positive for CLU (0, 0-10% positive cells; 1, 10-30% positive cells; 2, 30-70% positive cells; 3, over 70% positive cells). A final score of ≥2 points was considered positive, whereas a final score of <2 points was considered negative.
Statistical Analysis
Univariate analysis of overall survival was used to assess the main risk factors for breast cancer survival. Kaplan-Meier survival analysis was done to assess prognosis of breast cancer patients. An unpaired t test was used to determine the significance of differences in CLU expression among normal adjacent tissues and breast cancer tissues with and without lymph node metastasis. Correlation analyses were used to assess the relationship between CLU expression and tumor volume. Statistical analysis software SPSS 10.0 (Chicago, Illinois) was used. P values less than 0.05 were considered statistically significant.
Results
Survival Analysis of Breast Cancer Patients
The relationship between prognosis of breast cancer patients and clusterin expression, patient age, recurrence, lymph node metastasis, pathological classification, tumor volume, presence of pre-surgery chemotherapy, and frequency of post-surgery chemotherapy was assessed. The results indicated that the survival time of patients with positive CLU expression, lymph node metastasis, and limited post-surgery chemotherapy (<6 cycles of treatment) was significantly shorter than that of patients without significant CLU expression (P=0.000), without lymph node metastasis (P=0.000) and more thorough post-surgery chemotherapy (≥6 cycles of treatment) (P=0.035). We concluded that CLU expression, lymph node metastasis, and the thoroughness of post-surgery chemotherapy influenced the prognosis and survival of these patients (Table II ; Figures 1-3) .
Clusterin Immunohistochemical Staining Coefficient in Relation to Lymph Node Metastasis and Adjacent Tissues
In order to avoid orientation errors and to facilitate the study, all the 158 breast cancer tissues were made into tissue microarray. After immunohistochemical staining, the cores of breast cancer microarray are intact and there were not obvious tissue sample spots leak. In our study, we used the mature sCLU α and β subunits that only detected CLU expression in the endoplasmic reticulum and extracellular space and not in the nucleus. Tumor cells showed strong cytoplasmic staining of CLU. Some tumor cell membranes were also positive, but with less intensity. Tumor cells nucleoli were positive for CLU expression ( Figure 5 A-C).
Univariate analysis of overall survival indicated that CLU expression, adjacent lymph node metastasis and ≥6 cycles of chemotherapy were significant factors in prognosis of the breast cancer patients (P=0.045, Table II ). Clusterin expression in tumor cells was higher than in normal adjacent breast epithelial cells (P=0.03, Table III ). Table  IV shows that the clusterin staining coefficient of breast cancer tissues in patients with lymph node metastasis was higher than that in patients without lymph node metastasis (P=0.000).
Discussion
Despite recent advances in treatment, breast cancer remains a considerable threat for women. The incidence of breast cancer has increased two percentage points per year in China over the past 20 years, so the occurrence of these tumors is now two times more frequent than in the 1980s (14-15). The frequency is increasing, especially in younger-aged groups (16). Breast cancer patients are generally in the latter part of middle age or older in western developed countries, but in China they are younger. Nab et al. (17) reported the median age as 56.5 years old in 2052 Surgical removal of the tumor followed by systemic treatment is the main protocol for breast cancer therapy. Seventy percent of breast cancer patients remain disease-free after 5-years; 50% of patients remain disease-free after 10-years. Thirty 0.00 20.00 40.00 60.00 80.00 100.00 120.00 140.00 160.00 percent of patients diagnosed with late stage disease die of recurrence and metastasis (18). Early detection and anti-metastasis therapy is important to increase the cure and survival rates of breast cancer patients. Numerous clinical studies have indicated that 70%-80% of patients with lymph node metastasis will be diagnosed with recurrence or metastasis within 10-years, and 20-30% without lymph node metastasis will be diagnosed with distant metastasis (19) (20) (21) . We concluded that CLU expression, adjacent lymph node metastasis, and cycles of chemotherapy after surgery were the main risk factors for poor prognosis. These data suggest early diagnosis and therapy could also prolong the disease-free periods. The length of the disease-free period is also influenced by the number of chemotherapy treatments, and standard auxiliary chemotherapy seems to prolong the life of breast cancer patients.
Survival time (months)
Neoadjuvant chemotherapy can enhance the effect of surgery and prolong the disease-free period. The survival time of breast cancer patients with more thorough pre-surgery chemotherapy (≥6 cycles of treatment) is longer than that of patients who received limited pre-surgery chemotherapy (<6 cycles of treatment). Breast cancer patients at Tianjin Cancer Hospital between 1993 and 1994 also regularly received tamoxifen therapy in addition to surgery or surgery and chemotherapy.
Clusterin (CLU), also known as apolipoprotein J, TRPM-2, Xip8, or SGP-2, is a stress-induced glycoprotein (3). The CLU gene, located on human chromosome 8q21, encodes a protein of 448 amino acids (7, 22) . It was first identified from testis and is detected in fluid of various tissues. It is involved in many processes including lipid transport, differentiation of epithelial cells, tissue remodeling, and apoptosis (7, 8). CLU expression is induced in some diseases such as Alzheimer's disease (23). CLU is a marker for apoptosis, as it participates in the cellular apoptotic response (24-26). The relationship between CLU protein and tumorigenesis depends on the clusterin subtype, localization, and glycosylation of CLU. Some reports indicate that pro-CLU, which must be glycosylated, participates in tumorigenesis. Precursor nuclear CLU is located in the cytosol and nucleus of the cells, and mature glycosylated CLU is found in the endoplasmic reticulum (27) (28) (29) . nCLU may be a pro-apoptotic factor, signaling for cell death when abnormal duplication is detected in order to inhibit tumorigenesis. Mature glycosylated secretory CLU in the cytoplasm promotes tumorigenesis (30) (31) (32) . Other reports suggested that apoptotic and survival signals in rat prostate cells were located in different subtypes of CLU (4, 33, 34) . The apoptotic subtype of CLU localized to the cytosol and nucleus, while the survival subtype localized in the endoplasmic reticulum (35) (36) (37) (38) . CLU in the cytoplasm may, therefore, correlate to cell survival.
In this study, the antibody that was used targeted mature sCLU α and β subunits, and it detected CLU expression in the cytoplasm, not in the nucleus. CLU expression was higher in tumor tissue than in normal adjacent breast epithelial tissue in 158 cases of breast cancer patients. The survival time of breast cancer patients with CLU positive expression was significantly shorter than that for patients with negative expression. Lymph node metastasis occurred more often in patients with CLU positive expression than in those with negative expression. CLU expression in breast cancer tissues was higher than it was in normal adjacent tissues. Collectively, these data suggest that CLU overexpression is secondary to the main genetic and molecular lesions responsible for development, growth, and metastasis of breast cancer. The mechanisms of the different CLU subtypes and their distinct localizations have not been investigated in relation to tumorigenesis. The exact functions of the different subtypes also need to be elucidated. 
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